Anti-NMDA Receptor Encephalitis clinical trials at University of California Health
2 in progress, 1 open to eligible people
ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
open to eligible people ages 12 years and up
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
at UC Davis UC Irvine
(PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
Sorry, in progress, not accepting new patients
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
at UCSD UCSF
Our lead scientists for Anti-NMDA Receptor Encephalitis research studies include Xiao-Tang Kong, MD Mustafa Ansari, MD Jeffrey Gelfand.
Last updated: